Unknown

Dataset Information

Adverse cardiovascular events in patients treated with mogamulizumab.


ABSTRACT:

Study objectives

Mogamulizumab is an important treatment for T-cell leukemia and lymphoma. Adverse cardiovascular events (ACE) after mogamulizumab therapy have not been investigated. The aim of the study is to investigate ACE occurrence after mogamulizumab therapy.

Methods

The International World Health Organization database, VigiBase, was analyzed from January 2013 to August 2019 for all adverse events, including ACE, that occurred after mogamulizumab treatment. ACE was defined as: cardiac death, myocardial infarction, heart failure, myocarditis, arrhythmia, vasculitis, thrombosis, palpitations and new hypertension.

Results

ACE after mogamulizumab therapy affected 28 out of 650 unique patients (4.3%). Heart failure (42.8%) and ventricular arrhythmias (17.85%) were mo

SUBMITTER: Kwan JM 

PROVIDER: S-EPMC10978139 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature